Table 1.
Patient Characteristics
| Patient Characteristics | LTBI (n = 91) | Non-LTBI (n = 2440) | ||
|---|---|---|---|---|
| N | (%) | N | (%) | |
| Median age, years (range) | 55 | 19–74 | 57 | 18–77 |
| Male sex | 53 | 58.2 | 1424 | 58.4 |
| Race | ||||
| White | 53 | 58.2 | 2237 | 91.7 |
| Black | 6 | 6.6 | 49 | 2.0 |
| Asian | 11 | 12.1 | 34 | 1.3 |
| Mixed | 5 | 5.5 | 32 | 1.3 |
| Unknown | 16 | 17.6 | 88 | 3.6 |
| Underlying malignancy for auto-HCT | N = 47 | N = 1205 | ||
| Multiple myeloma | 35 | 74.5 | 717 | 59.5 |
| Non-Hodgkin lymphoma | 10 | 21.3 | 360 | 29.9 |
| Hodgkin’s disease | 2 | 4.3 | 106 | 8.8 |
| Underlying malignancy for allo-HCT | N = 44 | N = 1235 | ||
| Acute myelogenous leukemia | 17 | 38.6 | 445 | 36.1 |
| Non-Hodgkin lymphoma | 3 | 7.8 | 203 | 16.4 |
| Myelodysplastic syndrome | 10 | 22.7 | 192 | 15.6 |
| Acute lymphocytic leukemia | 5 | 11.4 | 110 | 8.9 |
| Allogeneic HCT-specific Parameters | N = 44 | N = 1235 | ||
| Myeloablative conditioning | 21 | 47.7 | 402 | 32.6 |
| Reduced-intensity conditioning | 23 | 52.3 | 833 | 67.4 |
| Source of hematopoietic cells | ||||
| Peripheral blood | 33 | 75.0 | 1070 | 86.6 |
| Bone marrow | 9 | 20.5 | 108 | 8.7 |
| Cord blood | 2 | 4.5 | 57 | 4.6 |
| Allogeneic donor characteristics | ||||
| Matched-related donor | 13 | 29.5 | 375 | 30.4 |
| Matched-unrelated donor | 22 | 50.0 | 656 | 53.1 |
| Mismatched donor | 9 | 20.5 | 204 | 16.5 |
| GVHD Prophylactic regimens | ||||
| MTX and tacrolimus | 15 | 34.1 | 451 | 36.7 |
| MTX, tacrolimus, and sirolimus | 12 | 27.3 | 365 | 29.7 |
| Sirolimus and tacrolimus | 10 | 22.7 | 235 | 19.1 |
| Other | 7 | 15.9 | 184 | 14.9 |
| Acute GVHD | 22 | 50.0 | 528 | 42.8 |
Abbreviations: GVHD, graft-versus-host disease; HCT, hematopoietic cell transplant; LTBI, latent tuberculosis infection; MTX, methotrexate.